Overall, these data suggest that targeting NEDD9-associated pathways such as the AURKA-HDAC6-CTTN signaling is a promising strategy for preventing CLL homing, thus limiting disease progression (Fig. 6F). Here, HDAC6 is linked to B-cell chronic lymphocytic leukemia.